by Chatelain E. Journal of Biomolecular Screening 2014, doi: 10.1177/1087057114550585.
Summary: New drugs for Chagas disease that are safe, efficacious, low cost, and adapted to the field are critically needed, and over the past five years, there has been increased interest and a surge in activities within various organizations. However, recent clinical trials with azoles were disappointing, and the lack of translation from in vitro and in vivo models to the clinic observed raises several questions. There is a scientific requirement to review and challenge whether we are indeed using the right tools and decision-making processes to progress compounds forward for the treatment of this disease. New developments in the Chagas field, including new technologies and tools now available, are discussed, and a redesign of the current screening strategy during the discovery process is proposed.